Apogee Therapeutics slides as recent $350M equity offering overhang weighs on shares
Apogee Therapeutics shares are lower on April 29, 2026 as investors continue to digest recent equity financing that increased share count and raised dilution concerns. The company closed a $350 million underwritten public offering in late March, and secondary-offering aftereffects are still pressuring the stock.
1) What’s moving the stock today
Apogee Therapeutics (APGE) is down about 3.21% to $82.68 on Wednesday, April 29, 2026, amid lingering pressure tied to its recent equity raise. Stocks often drift lower after large secondaries as traders price in added supply, hedge activity, and dilution from newly issued shares.
2) The financing catalyst in focus
In late March, Apogee launched a $300 million underwritten public offering and then priced a larger deal: 5.0 million shares at $70.00 per share for $350 million in gross proceeds, with the transaction closing on March 26, 2026. Even when the cash strengthens the balance sheet, the near-term market reaction can be negative because the financing increases the share base and can create a temporary “offering overhang” as new shares find long-term holders. (investors.apogeetherapeutics.com)
3) What to watch next
With the financing now completed, investors are refocusing on timeline and execution risk in Apogee’s inflammatory and immunology pipeline, plus the next scheduled corporate updates such as quarterly results. The next earnings date is widely estimated for mid-May 2026, which can also amplify day-to-day volatility as positioning shifts into the event. (marketbeat.com)